Made Scientific and Basilard BioTech Collaborate to Accelerate Development of Celletto Gene Delivery Platform

Strategic Insights -

Made Scientific, a leading US-based cell therapy contract development and manufacturing organization (CDMO), and Basilard BioTech, a Southern California biotechnology company, have announced a strategic collaboration to accelerate the development and translation of Basilard BioTech's nanomechanical gene delivery platform, Celletto. Celletto is a disruptive technology that addresses long-standing limitations of viral vectors and conventional non-viral methods, enabling exceptionally high transfection efficiency while preserving cell viability and function.

Key Takeaways:

  • Celletto is a nanomechanical gene delivery technology that achieves exceptionally high transfection efficiency while preserving cell viability and function.
  • Celletto delivers superior cell viability, maintaining functional integrity of sensitive cell types, including T cells and induced pluripotent stem cells (iPSCs).
  • The technology achieves high gene transfer efficiency, reliable and reproducible delivery of genetic payloads across diverse constructs, including large plasmids and gene-editing components.
  • Celletto is scalable and flexible, engineered on silicon wafers as a modular platform adaptable for both small-scale research use and GMP-compliant large-scale manufacturing.
  • The technology reduces cost and manufacturing complexity, eliminating dependence on viral vectors and shortening production timelines.
  • Made Scientific's Center of Excellence for Process and Analytical Development and state-of-the-art GMP manufacturing facility in Princeton, NJ, will be used to validate and scale the Celletto platform.
  • Initial data readouts are expected by the end of Q3 2025, with results and presentation at upcoming industry conferences.

Statistics:

  • Celletto achieves superior cell viability, maintaining functional integrity of sensitive cell types, including T cells and iPSCs.
  • The technology enables high gene transfer efficiency, achieving reliable and reproducible delivery of genetic payloads across diverse constructs.
  • Celletto is scalable and flexible, adaptable for both small-scale research use and GMP-compliant large-scale manufacturing.
  • The technology reduces cost and manufacturing complexity, eliminating dependence on viral vectors and shortening production timelines.
  • Made Scientific's Center of Excellence for Process and Analytical Development has a global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors.

Sources:

  • Made Scientific, Inc. (2025, September 15). Made Scientific and Basilard BioTech Announce Strategic Collaboration to Accelerate Celletto Gene Delivery Platform. PR Newswire.
  • Basilard BioTech (n.d.). About Us. Retrieved from https://www.basilardbiotech.com/about/.
  • Made Scientific (n.d.). About Us. Retrieved from https://www.madescientific.com/about-us.